The long-term maintenance of CHR status combined with the reduction in allele burden show that prolonged ropegIFN treatment can lead to a durable response and greater efficacy than short-term treatment, and may lead to an operational cure for PV (defined as a JAK2 V617F allele burden ≤ 10%, a CHR maintained for ≥ 2 years, and no disease progression, thromboembolic events, or worsening of symptoms) [8]. This evidence concerns the gene JAK2 and acquired polycythemia vera.